Sparks commentary - BB Biotech

Investment Companies

Sparks - BB Biotech

More on this equity
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
BB Biotech (SIX: BION) – Vertex to acquire Crinetics Pharmaceuticals
Published by Arron Aatkar, PhD

Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals. This is particularly noteworthy for BB Biotech since both Vertex (10.4%) and Crinetics (4.2%) were portfolio holdings as of 31 March 2026. More broadly, BB Biotech noted that the transaction provides further evidence of strategic value being created across the biotech sector, reinforcing the company’s conviction that innovation, clinical progress and commercial potential remain central to long term value creation.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.